30 assets in Schizoaffective Disorder

Therapeutic assets addressing Schizoaffective Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dexmedetomidine Schizoaffective Disorder	BioXcel Therapeutics Inc	P4	BBB (77)
Olanzapine Schizoaffective Disorder	The Royal Ottawa Mental Health Centre	P4	BBB (77)
Risperidone Schizoaffective Disorder	Lyndra Inc.	P4	BBB (77)
Topiramate Schizoaffective Disorder	Mayo Clinic	P4	BBB (74)
Serine D-Form Schizoaffective Disorder	University of Minnesota	P3	BBB (72)
Clozapine Schizoaffective Disorder	The Royal Ottawa Mental Health Centre	P4	BB (70)
Lorazepam Schizoaffective Disorder	Temple University	P4	BB (69)
Naltrexone Schizoaffective Disorder	Mayo Clinic	P4	BB (69)
Minocycline Schizoaffective Disorder	Pakistan Institute of Living and Learning	P4	BB (68)
MT-5199 Schizoaffective Disorder	Neurocrine Biosciences	P4	BB (68)
Nicotine Schizoaffective Disorder	Wake Forest University Health Sciences	P4	BB (68)
Varenicline Schizoaffective Disorder	University of California, San Diego	P4	BB (68)
Bazedoxifene Schizoaffective Disorder	The Alfred	P4	BB (65)
Etomidate Schizoaffective Disorder	Yeongseok Yun	P4	BB (65)
il-23 Schizoaffective Disorder	University of Maryland, Baltimore	P4	BB (65)
Lumateperone Schizoaffective Disorder	University of Massachusetts, Worcester	P4	BB (65)
Modafinil Schizoaffective Disorder	University of Minnesota	P4	BB (65)
Olanzapine-Samidorphan Schizoaffective Disorder	New York State Psychiatric Institute	P4	BB (65)
Remimazolam Schizoaffective Disorder	Yeongseok Yun	P4	BB (65)
Semaglutide Schizoaffective Disorder	Mayo Clinic	P4	BB (65)
Cogentin Schizoaffective Disorder	University of Pittsburgh	P4	B (63)
Benzoic Acid Schizoaffective Disorder	National Cheng-Kung University Hospital	P2	B (57)
Methylphenidate Schizoaffective Disorder	The Royal Ottawa Mental Health Centre	P2	B (57)
Dextrose Schizoaffective Disorder	Beth Israel Deaconess Medical Center	P2	CCC (53)
Rituximab Schizoaffective Disorder	Uppsala University Hospital	P2	CCC (53)
Trospium Schizoaffective Disorder	New York State Psychiatric Institute	P1/2	CCC (48)
Xanomeline Schizoaffective Disorder	New York State Psychiatric Institute	P1/2	CCC (48)
Acetazolamide Schizoaffective Disorder	Vishwajit Nimgaonkar, MD PhD	P1/2	CC (47)
Cromoglycate Schizoaffective Disorder	Vishwajit Nimgaonkar, MD PhD	P1/2	CC (47)
Ocrelizumab Schizoaffective Disorder	The Methodist Hospital Research Institute	P1/2	NR ()